Bernstein Liebhard LLP Announces Investigation of Acquisition of Martek Biosciences Corporation by DSM
December 21 2010 - 9:15AM
Business Wire
Bernstein Liebhard LLP is investigating whether the Board of
Directors of Martek Biosciences Corporation (“Martek” or the
“Company”) (NASDAQ: MATK) breached its fiduciary duty to its
shareholders in agreeing to sell Martek to DSM.
Under the terms of the agreement, Martek shareholders will
receive $31.50 in cash for each share they own. The investigation
is focused on the potential unfairness of the price to Martek
shareholders and the process by which the Martek Board of Directors
considered and approved the transaction.
If you are interested in discussing your rights as a Martek
shareholder and/or have information relating to the matter, please
contact U. Seth Ottensoser at (877) 779-1414 or
Ottensoser@bernlieb.com.
Bernstein Liebhard has pursued hundreds of securities, consumer
and shareholder rights cases and recovered almost $3 billion for
its clients. It has been named to The National Law Journal’s
“Plaintiffs’ Hot List” in each of the last eight years.
Bernstein Liebhard LLP10 East 40th StreetNew York, New York
10016(877) 779-1414www.bernlieb.com
ATTORNEY ADVERTISING. © 2010 Bernstein Liebhard LLP. The law
firm responsible for this advertisement is Bernstein Liebhard LLP,
10 East 40th Street, New York, New York 10016, (212) 779-1414.
Prior results do not guarantee or predict a similar outcome with
respect to any future matter.
Martek (NASDAQ:MATK)
Historical Stock Chart
From Jun 2024 to Jul 2024
Martek (NASDAQ:MATK)
Historical Stock Chart
From Jul 2023 to Jul 2024
Real-Time news about Martek Biosciences Corp. (MM) (NASDAQ): 0 recent articles
More Bernstein Liebhard LLP News Articles